CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives

References

• Vellenga E, Griffin JD. The biology of acute myeloid leukemia. Semin Oncol 1982;14:365–371.
   Google Scholar
• Brunning RD, Vardiman J, Matutes E et al. Acute myeloid leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues. Geneva: World Health Organization; 2001. p 77–105.
   Google Scholar
• Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322–2333.
   Google Scholar
• Strout MP, Marcucci G, Caligiuri MA, Bloomfield CD. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Ann Hematol 1999;78:251–264.
   PubMed Web of Science ®Google Scholar
• Baer MR, Bloomfield CD. Multidrug resistance in acute myeloid leukemia. J Natl Cancer Inst 1991;83:663–665.
   PubMed Web of Science ®Google Scholar
• Marucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000;18:768–780.
   Google Scholar
• Appelbaum FR. Molecular diagnosis and clinical decisions in adult acute leukemia. Semin Hematol 1999;36:401–410.
   PubMed Web of Science ®Google Scholar
• Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer 2001;92:1059–1073.
   PubMed Web of Science ®Google Scholar
• Estey EH. Prognostic factors in acute myelogenous leukemia. Leukemia 2001;15:670–672.
   PubMed Web of Science ®Google Scholar
• Tomblyn MR, Tallman MS. New developments in antibody therapy for acute myeloid leukemia. Semin Oncol 2003;30:502–508.
   PubMed Web of Science ®Google Scholar
• Giles FJ. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev Anticancer Ther 2002;2:630–640.
   PubMedGoogle Scholar
• Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003;98:2095–2104.
   Google Scholar
• Freeman SD, Kelm S, Barber EK, Crocker PR. Characteriza-tion of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 199585:2005-2012.
   PubMed Web of Science ®Google Scholar
• Crocker PR. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr Opin Struct Biol 2002;12:609–615.
   PubMed Web of Science ®Google Scholar
• Bernstein ID. CD33 as target for selective ablation of acute myeloid leukemia. Chin Lymphoma 2002;2(Suppl.):S9–S11.
   Google Scholar
• Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738–743.
   Google Scholar
• Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Schernthaner GH, Wacheck V, Selzer E, Sperr WR, Valent P. Expression of the target receptor CD33 on leukemic stem cells in patients with AML. Submitted.
   Google Scholar
• Sperr WR, Hauswirth AW, Florian S, Ohler L, Geissler K, Valent P. Human leukaemic stem cells: a novel target of therapy. Eur J Chin Invest 2004;34:31–40.
   PubMed Web of Science ®Google Scholar
• Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000;14:474–475.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Appelbaum FR, Spielberger RT et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678–3684.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML et al. Mylotarg® Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19: 3244–3254.
   Google Scholar
• Roboz GJ, Knovich MA, Bayer RL, Schuster MW, Seiter K, Powell BL, Woodruff RD, Silver RT, Frankel AE, Feldman EJ. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. L,euk Lympho-ma 2002;43:1951–1955.
   PubMed Web of Science ®Google Scholar
• Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB et al. Mylotarg Study Group. Antibody-targeted chemother-apy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16:1627–1636.
   Google Scholar
• Estey EH, Thall PF, Giles FJ, Wang X1\4, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idaru-bicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;99: 4343–4349.
   Google Scholar
• Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp Met al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;104:1995–1999.
   Google Scholar
• Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003;51:87–90.
   Google Scholar
• Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 2002;50:497–500.
   PubMed Web of Science ®Google Scholar
• Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, Cortes JE, Kantarjian HM. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;99:4222–4224.
   Google Scholar
• Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelo-genous leukemia or high-risk myelodysplastic syndromes. Cancer 2003;97:1481–1487.
   Google Scholar
• Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003;27:887–891.
   PubMed Web of Science ®Google Scholar
• Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW. A feasibility study of simultaneous administration of gemtuzu-mab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003;102:4277–4283.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003;52:449–452.
   Google Scholar
• Saviola A, Luppi M, Potenza L, Morselli M, Ferrari A, Riva G, Torelli G. Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treat-ment with defibrotide. Br J Haematol 2003;4: 752.
   Google Scholar
• Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Gulden P. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzu-mab ozogamicin exposure. Blood 2004;103:1968.
   PubMed Web of Science ®Google Scholar